Connect with us

Hi, what are you looking for?

Medicine

Todos Medical to Host Business Update Conference Call on December 2nd at 4:30 PM EST

New York, NY, and Tel Aviv, ISRAEL – December 1, 2021 – Todos Medical, Ltd. (“Todos Medical”) (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that the management team of Todos Medical, including Mr. Gerald E. Commissiong, President and Chief Executive Officer, will host a conference call on Thursday, December 2nd at 4:30 p.m. EST to discuss the Company’s business progress in 2021 and provide a strategic outlook for the future.

The call information is as follows: 

Date:  December 2, 2021

Time:  4:30 p.m. Eastern Standard Time
Direct Dial-in number: (669) 900-6833

Meeting ID: 94945983568

Passcode: 167897 

This call is being webcast and can be accessed at https://audience.mysequire.com/webinar-view?webinar_id=6b97aec0-7ccb-4754-9a33-5c26d34d9597.

The call will also be available for replay by accessing https://audience.mysequire.com/webinar-view?webinar_id=6b97aec0-7ccb-4754-9a33-5c26d34d9597.

For more information, please visit www.todosmedical.com. For more information on the Company’s CLIA/CAP certified lab Provista Diagnostics, Inc. please visit www.provistadx.com.

About Todos Medical Ltd.

Founded in Rehovot, Israel with offices in New York City, Todos Medical Ltd. (OTCQB: TOMDF) engineers life-saving diagnostic solutions for the early detection of a variety of cancers. In 2021, Todos completed the acquisition of U.S.-based medical diagnostics company Provista Diagnostics, Inc. to gain rights to its Alpharetta, Georgia-based CLIA/CAP certified lab currently performing PCR COVID testing and Provista’s proprietary commercial-stage Videssa® breast cancer blood test. The Company’s state-of-the-art and patented Todos Biochemical Infrared Analyses (TBIA) is a proprietary cancer-screening technology using peripheral blood analysis that deploys deep examination into cancer’s influence on the immune system, looking for biochemical changes in blood mononuclear cells and plasma. Todos’ two internally-developed cancer-screening tests, TMB-1 and TMB-2, have received a …

Full story available on Benzinga.com

Source Here: benzinga.com

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Medicine

Arbutus’ Lead Compound AB-729 Continues to be Safe and Effective at Reducing HBsAg in Patients with Chronic Hepatitis B HBsAg remains suppressed up to...

Arts

The Fourth Single ‘Eyy Bidda Idhi Naa Adda’ From Allu Arjun’s Pushpa Is Out… The Fourth Single ‘Eyy Bidda Idhi Naa Adda’ From Allu...

Arts

Kyle Rittenhouse testifies about Gaige Grosskreutz holding a gun toward him during his trial at the Kenosha County Courthouse on November 10, 2021 in...

Medicine

PHILADELPHIA, Nov. 09, 2021 (GLOBE NEWSWIRE) — AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC, the “Company”)), a biotechnology company with operations in China and the...

ONBP.com